Navigation Links
MDS Nordion Provides Update on AECL's Medical Isotope Supply Disruption
Date:5/19/2009

OTTAWA, May 19 /PRNewswire-FirstCall/ - MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, has received information from its primary supplier, Atomic Energy of Canada Limited (AECL), regarding an interruption in the supply of medical isotopes, primarily molybdenum-99 (Mo-99) used in the manufacturing of technetium-99m generators.

AECL has advised MDS Nordion that they anticipate the National Research Universal reactor (NRU) will remain out of service for more than one month. According to a press release issued by AECL on May 18, 2009, the shutdown is a result of a heavy water leak that has been identified at the base of the reactor vessel. AECL has indicated that repair options are currently under consideration.

MDS Nordion expects the impact of this shutdown to begin to be felt this week. The NRU produces approximately 30%-40% of the world's medical isotopes and approximately 50% of those used in North America, and is one of only four reactors in the world with the capacity to produce significant commercial quantities. While MDS Nordion is working closely with its supply network to source additional isotopes, based on AECL's information and global supply capability, the Company expects that the medical community and their patients will experience a significant shortage of isotopes worldwide.

MDS Nordion recognizes the important role medical isotopes play in the diagnosis and treatment of life-threatening conditions such as heart disease and cancer. The Company continues to work to secure a reliable, long-term supply of medical isotopes. In 1996, MDS Nordion contracted for AECL to complete and commission the MAPLE reactors, which were meant to replace the NRU. This project was unilaterally discontinued in May 2008 by the federal government and AECL. MDS Inc.'s investment in the MAPLE project was approximately US$350 million. MDS believes that the completion of the MAPLE project is the best alternative to provide long-term global isotope supply.

In addition to MAPLE, MDS Nordion is examining longer-term supply alternatives. One such program is MDS Nordion's recently announced collaboration with TRIUMF, Canada's national laboratory for particle and nuclear physics, to study the feasibility of producing a viable and reliable supply of photo fission-based Mo-99.

Based on this latest update from AECL, MDS Inc. expects the financial impact of this extended interruption to reduce MDS Nordion's adjusted EBITDA by approximately US$4 million per month.

More Information

Additional background pertaining to today's announcement can be found on MDS Inc.'s Website at http://www.mdsinc.com/for_media/electronic_media_kit.asp

About MDS Nordion

MDS Nordion, a business unit of MDS Inc., is a global leader in providing medical isotopes for molecular and diagnostic imaging, radiotherapeutics and sterilization technologies for medical products that benefit the lives of millions of people in more than 50 countries around the world. MDS Nordion products and services are used on a daily basis by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Find out more at www.mdsnordion.com

About MDS

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs, and the diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 5,000 highly skilled people in 29 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.

Forward-Looking Statements

This document contains forward-looking statements. Some forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "indicates", "targeted" or similar expressions. The statements are not a guarantee of future impact or performance and are inherently subject to risks and uncertainties. The actual impact to the Company of the maintenance shutdown could differ materially from that currently anticipated due to a number of factors, including, the actual timing of a return to full production and other risk factors identified in other documents filed by the Company with Canadian and U.S. securities regulatory authorities from time to time.


'/>"/>
SOURCE MDS Nordion
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MDS Nordion Launches Improved TheraSphere(R) Administration System for Physicians
2. Dr. Peter Covitz Joins MDS Nordion as Senior Vice-President Innovation
3. MDS Nordion Provides Update to Medical Isotope Customers
4. MDS Nordion Divests Non Strategic Product Lines
5. MDS Nordion signs 17-year contract with Rosenergoatom
6. Taking a Bite Out of Rabies: Merial Provides Rabies Awareness and Prevention Training to Noahs Wish Pet Disaster Relief Organization
7. Mayo Clinic Researchers Say Agent Provides Treatment Option for Women with Hot Flashes
8. National Autism Association Provides Funds to Law Enforcement Agencies in Staunton, Virginia and Summit County, Utah for Project Lifesaver Equipment
9. All Allied Health Schools Provides Public Health Students with Career and Education Resources
10. Mayo Clinic researchers say agent provides treatment option for women with hot flashes
11. MTF, Largest Tissue Bank, Provides Skin for Victims of Santa Barbara Wildfires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... , ... The Anaheim Hills office accelerates and supports FNCC’s growth and further ... sales professionals over the past 6 months and is continuing to recruit new talent ... course of 2017. , “This new office is a direct result of our ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... with opioids alone responsible for over 33,000 of the 52,404 drug-related deaths in ... Bill (AB) 1512, which proposes a tax on prescription opioids to fund drug ...
(Date:3/25/2017)... ... ... Swissray is pleased to announce the release of the ELITE DXA, a new bone ... scan window, which is more than double that of existing bone densitometers. Historically, subjects ... an accurate total body bone density or body composition study. The ELITE DXA ...
(Date:3/24/2017)... ... March 24, 2017 , ... Digital Scientists, a software innovation lab specializing in ... a Greenville, South Carolina location. The lab has set up shop at ... been working with South Carolina clients for years from our office here in Atlanta,” ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... related services to families and business owners across eastern Michigan, is connecting with ... families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... March 27, 2017  A recent study at Shriners ... freestanding hospitals in the country dedicated to the treatment ... surgery, concluded that the Surfacide Helios ® UV-C ... in reducing bacterial pathogens not killed by the EVS ... at the American Burn Association,s 49th Annual Meeting in ...
(Date:3/27/2017)... , March 27, 2017 ... 7,000 attendees and more than 600 exhibitors from ... discover opportunities and solutions that will advance the ... April 2017 at the Messe Stuttgart, ... preeminent medical technology platform showcasing the key trends ...
(Date:3/27/2017)... March 27, 2017  Sophiris Bio Inc. (NASDAQ: ... a clinical late-stage biopharmaceutical company developing topsalysin (PRX302) ... today reported fourth quarter and full year 2016 ... Key Corporate Highlights: Advanced ... Cancer. During 2016, the Company reported successful results ...
Breaking Medicine Technology: